StockNews.AI
ANIP
StockNews.AI
182 days

ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025, at 8:00 a.m. ET

1. ANI Pharmaceuticals will report Q4 and full-year 2024 results on Feb 28. 2. CEO Nikhil Lalwani will host a conference call after the results release. 3. Focus on Rare Disease products indicates potential growth opportunities.

Earnings
+1.8%Current Return
VS
+0.36%S&P 500
$58.9302/18 04:09 PM EDTEvent Start
$59.9902/19 09:47 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Bullish?

Positive earnings expectations and new product lines can drive investor confidence. Similar past announcements saw price increases for ANIP.

How important is it?

Earnings announcements are critical for stock performance; strong results can lead to stock appreciation.

Why Short Term?

The upcoming earnings call and financial results will have immediate impact. Prior earnings calls have influenced stock movements significantly.

Related Companies

ANIPGILDAMGN
February 18, 2025 16:05 ET  | Source: ANI Pharmaceuticals, Inc. PRINCETON, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its fourth quarter and full year 2024 financial results on Friday, February 28, 2025, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease, will host a conference call to discuss the results as follows: Date Friday, February 28, 2025  Time8:00 a.m. ET  Toll free (U.S.) 800-579-2543  Conference ID4860276  Webcast (live and replay) www.anipharmaceuticals.com, under the “Investors” section   A replay of the conference call will be available within two hours of the call’s completion and will remain accessible for two weeks by dialing 800-756-0554 and entering access code 4860276. About ANI Pharmaceuticals, Inc. ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Established Brands business. For more information, visit www.anipharmaceuticals.com. Investor Relations Contact:Lisa M. Wilson, In-Site Communications, Inc.212-452-2793lwilson@insitecony.com SOURCE: ANI Pharmaceuticals, Inc.

Related News